[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)].
After the single-dose application of Migräne-Kranit, a combination of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital, tablets and suppositories in six healthy male volunteers aged from 24 to 28 years, serum concentrations were determined. The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets. The lag-times and the absorption rates for the substances in both formulations differ significantly. The absorption rates for the substances in the tablet are faster than for those in the suppository. The estimates for the elimination rates show only small differences between the two formulations.
D000082:Acetaminophen / Q000008:administration & dosage / Q000378:metabolism; D000328:Adult; D000700:Analgesics / Q000378:metabolism*; D000983:Antipyrine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism; D002110:Caffeine / Q000008:administration & dosage / Q000378:metabolism; D004338:Drug Combinations / Q000008:administration & dosage / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008297:Male; D010208:Papaverine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism; D010634:Phenobarbital / Q000008:administration & dosage / Q000378:metabolism; D012007:Rectum; D013488:Suppositories; D013607:Tablets
D000700:Analgesics; D004338:Drug Combinations; D013488:Suppositories; D013607:Tablets; D000082:Acetaminophen; D002110:Caffeine; C028991:Migraine-Kranit; D010208:Papaverine; D000983:Antipyrine; D010634:Phenobarbital
Vergleichende Pharmakokinetik der Wirkstoffkombination Coffein, Ethaverin, Propyphenazon, Paracetamol und Phenobarbital aus einer Tabletten- und Suppositoriumzubereitung.